HTG Molecular Diagnostics has received notification of validation of European patent number EP 3356554 for its methods for subtyping diffuse large B-cell lymphoma (DLBCL), effective October 2019. HTG was previously granted a patent for this technology in the United States in 2018.
Lymphoma is the most common blood cancer, and DLBCL is the most common form of non Hodgkin’s lymphoma, accounting for up to 30 percent of newly diagnosed cases. There is no single, accepted diagnostic test for distinguishing germinal center B-cell-like (GCB) and non-GCB (for example, activated B-cell-like or ABC) DLBCL subtypes and/or for determining the prognosis of or treatment(s) for DLBCL patients.
“We are pleased to receive notification of the patent grant in Europe for our gene expression subtyping methodology used to distinguish the GCB vs. ABC subtypes for DLBCL,” said John Lubniewski, President and CEO of HTG. “We believe molecular subtyping may be used to better predict the prognosis and/or treatment of lymphoma patients who might benefit from such personalized medicine.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.